Susquehanna International Group
NRIX icon

Susquehanna International Group’s Nurix Therapeutics NRIX Stock Holding History

Susquehanna International Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$223K Sell
14,400
-48,400
-77% -$803K ﹤0.01% 11482
2025
Q4 		$1.19M Buy
+62,800
New +$902K ﹤0.01% 6793
2025
Q1 		– Sell
-32,700
Closed -$616K – 13140
2024
Q4 		$616K Sell
32,700
-10,700
-25% -$245K ﹤0.01% 8169
2024
Q3 		$975K Sell
43,400
-26,400
-38% -$598K ﹤0.01% 6843
2024
Q2 		$1.46M Buy
69,800
+51,400
+279% +$800K ﹤0.01% 5744
2024
Q1 		$270K Buy
+18,400
New +$198K ﹤0.01% 9937
2023
Q3 		– Sell
-10,200
Closed -$102K – 12646
2023
Q2 		$102K Buy
+10,200
New +$104K ﹤0.01% 10934

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Susquehanna International Group's NRIX Position: Q1 2026 in Review

Susquehanna International Group increased its Nurix Therapeutics (NRIX) stake by 61% in Q1 2026, buying an estimated $512K and bringing the position to 81,455 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #7299.

Susquehanna International Group first reported a position in NRIX in Q1 2021 and has held it in 21 quarters since. The position peaked at $1.77M in Q1 2021. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Susquehanna International Group held 81,455 shares of Nurix Therapeutics worth $1.26M as of Q1 2026.
  • Susquehanna International Group bought 30,902 Nurix Therapeutics shares in Q1 2026, an estimated $512K.
  • Nurix Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7299 holding.
  • Susquehanna International Group first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Susquehanna International Group's Nurix Therapeutics position peaked at $1.77M in Q1 2021.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.